CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) FY2026 Q2 Balance Sheet

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) FY2026 Q2 Balance Sheet

Balance sheet as of 2026-06-27. The chart shows assets, liabilities and equity at that date.

Assets

7,532,145,000 US dollars

Current assets

1,529,106,000 US dollars

Non-current assets

6,003,039,000 US dollars

Liabilities

4,643,618,000 US dollars

Current liabilities

1,134,746,000 US dollars

Non-current liabilities

3,508,872,000 US dollars

Equity

2,845,990,000 US dollars

Redeemable noncontrolling interests

42,537,000 US dollars

Noncontrolling interest

6,354,000 US dollars. Included in consolidated equity; this amount is not added again.

Trade receivables and contract assets, net of allowances for credit losses of $8,715 and $10,463, respectively

711,755,000 US dollars

Inventories

346,260,000 US dollars

Cash and cash equivalents

192,025,000 US dollars

Other current assets

178,657,000 US dollars

Prepaid assets

100,409,000 US dollars

Goodwill

3,076,851,000 US dollars

Property, plant and equipment, net

1,494,914,000 US dollars

Other assets

587,556,000 US dollars

Operating lease right-of-use assets, net

330,247,000 US dollars

Intangible assets, net

253,174,000 US dollars

Venture capital and strategic equity investments

206,470,000 US dollars

Deferred tax assets

53,827,000 US dollars

Accrued liabilities

380,101,000 US dollars

Other current liabilities

222,792,000 US dollars

Deferred revenue

203,035,000 US dollars

Accrued compensation

187,835,000 US dollars

Accounts payable

140,983,000 US dollars

Long-term debt, net and finance leases

2,619,985,000 US dollars

Operating lease right-of-use liabilities

407,708,000 US dollars

Other long-term liabilities

402,511,000 US dollars

Deferred tax liabilities

78,668,000 US dollars

Additional paid-in capital

1,986,023,000 US dollars

Retained earnings

1,372,295,000 US dollars

Common stock, $0.01 par value; 120,000 shares authorized; 49,550 shares issued and 47,728 shares outstanding as of June 27, 2026, and 49,217 shares issued and outstanding as of December 27, 2025

496,000 US dollars

Preferred stock, $0.01 par value; 20,000 shares authorized; no shares issued and outstanding

0 US dollars

Nonredeemable noncontrolling interest

6,354,000 US dollars

Treasury stock, at cost, 1,822 and zero shares, as of June 27, 2026 and December 27, 2025, respectively

negative 323,189,000 US dollars

Accumulated other comprehensive loss

negative 195,989,000 US dollars

Gross equity (calculated)

3,365,168,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

Chart connections

• Assets equal liabilities plus temporary equity plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
• Treasury shares and other negative equity contributions reduce equity.